How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?

How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?

How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Julio Rosenstock, MD

Julio Rosenstock, MD

Director, Dallas Diabetes and Endocrine Center
Clinical Professor of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas